Helen Fisher is a passionate leader with a rare combination of financial expertise and a deep knowledge of global networks in the life sciences sector.
Helen is CEO and managing director of Bio Capital Impact Fund (BCIF) and a director of BARD1 Life Sciences Ltd, a cancer diagnostics company. Helen was the chair of the Audit and Risk Committee at Sienna Cancer Diagnostics before it was acquired by BARD1. She is also the chair of the Victorian branch of AusBiotech.
Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte’s life sciences practice in Australia for 5 years, having had many years’ experience in the life sciences and health care sector.
She also specialised in the financial services sector, servicing some of the largest global and Australian banks and funds, as well as having advised on a number of significant M&A transactions.
Helen has provided strategic tax advice to publicly listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP and supply chain management.
Helen has Bachelor degrees in Law (with honours) and Science from the University of Melbourne, a Masters degree in Laws (specialising in International Taxation) from the University of Melbourne and a Masters degree in Commerce from the University of NSW.
“I am excited to join Calix’s team, because it enables me to contribute to commercialising Calix’s technology. I am confident that my skills in cross-border transactions and the global network that I’ve built will contribute to the growth story of Calix and aid in fulfilling its mission of solving global environmental challenges.”
